FORD KATHLEEN sold $112K of KURA

Kura Oncology (KURA) reported Q3 net loss of $70.2M, down 5% YoY. The company presented plans for ziftomenib, including combination studies and frontline trials, with top-line results expected in 2028. Kura also announced plans for darlifarnib studies and a financing agreement with Oberland Capital. Cash reserves stood at $492M, with guidance for 2026-2028 collaboration revenue.

Kura Oncology, Inc. (KURA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kura Oncology Reports THIRD Quarter 2026 Financial Results AND CORPORATE UPDATE – KOMZIFTI ® (ziftomenib) net product revenue grew 53% sequentially to $13.9 million; new patient starts increased 30% and total prescriptions grew 65% – – KOMZIFTI maintained majority sh

Kura Oncology (KURA) and Kyowa Kirin (4151) will present data on ziftomenib, their leukemia drug, at the 2026 ASH Annual Meeting. Key presentations include combination results with quizartinib and gilteritinib, longer-term data with venetoclax and azacitidine, and exploratory analysis in additional AML subtypes. The companies aim to establish ziftomenib as a preferred menin inhibitor for combination treatments. An investor webcast is scheduled for December 15, 2026.

Kura Oncology (NASDAQ:KURA) launched a $50M venture to develop KO-7246, an oral menin inhibitor for diabetes. Preclinical studies showed improved blood-sugar control in animals and increased beta-cell proliferation in human islet microtissues. The company plans to start clinical trials in 2024, aiming to assess safety and efficacy in diabetes patients.

Caspian Therapeutics and Kura Oncology (KURA) presented a development plan for KO-7246, an oral menin inhibitor for diabetes. Preclinical data showed potential to increase insulin production and improve glucose control. Caspian aims to start Phase 1 trials. KURA is down 4.14% at $9.94.

Caspian Therapeutics and Kura Oncology (KURA) will discuss the development strategy for KO-7246, an oral menin inhibitor for diabetes, in a webcast. Preclinical findings showed improved glucose control and beta cell expansion in animal models. Caspian plans to conduct a Phase 1 clinical trial to assess safety and insulin production. Kura owns half of Caspian and retains research collaboration rights.